Definitive Healthcare (NASDAQ:DH) Shares Up 1.8% - Still a Buy?

Definitive Healthcare Corp. (NASDAQ:DH - Get Free Report)'s stock price shot up 1.8% on Wednesday . The stock traded as high as $4.05 and last traded at $4.02. 687,326 shares changed hands during mid-day trading, a decline of 15% from the average session volume of 807,743 shares. The stock had previously closed at $3.95.

Analysts Set New Price Targets

Several brokerages recently weighed in on DH. Wall Street Zen raised shares of Definitive Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, June 21st. BTIG Research lowered shares of Definitive Healthcare from a "buy" rating to a "neutral" rating in a research note on Friday, May 9th. Finally, The Goldman Sachs Group increased their price target on shares of Definitive Healthcare from $3.00 to $3.40 and gave the company a "neutral" rating in a research note on Monday, May 12th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Definitive Healthcare has a consensus rating of "Hold" and a consensus target price of $5.10.

Definitive Healthcare Trading Down 4.5%

The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.75. The firm has a market capitalization of $570.78 million, a PE ratio of -0.87, a price-to-earnings-growth ratio of 6.77 and a beta of 1.64. The business's 50-day moving average price is $3.68 and its 200-day moving average price is $3.64.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.03. The business had revenue of $59.19 million for the quarter, compared to analyst estimates of $56.20 million. Definitive Healthcare had a negative net margin of 206.05% and a positive return on equity of 3.69%. The company's revenue for the quarter was down 6.8% compared to the same quarter last year. During the same period last year, the firm posted $0.08 earnings per share. As a group, analysts expect that Definitive Healthcare Corp. will post 0.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Definitive Healthcare

Several hedge funds have recently modified their holdings of DH. Goldman Sachs Group Inc. boosted its position in shares of Definitive Healthcare by 564.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company's stock worth $25,191,000 after purchasing an additional 7,404,363 shares in the last quarter. Irenic Capital Management LP raised its stake in shares of Definitive Healthcare by 9.2% during the 4th quarter. Irenic Capital Management LP now owns 7,003,194 shares of the company's stock worth $28,783,000 after buying an additional 590,009 shares during the last quarter. Palisade Capital Management LP raised its stake in shares of Definitive Healthcare by 1.3% during the 1st quarter. Palisade Capital Management LP now owns 2,265,198 shares of the company's stock worth $6,546,000 after buying an additional 29,774 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Definitive Healthcare by 1.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,863,912 shares of the company's stock valued at $7,661,000 after purchasing an additional 23,410 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Definitive Healthcare by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 1,272,660 shares of the company's stock valued at $5,231,000 after purchasing an additional 39,938 shares during the last quarter. 98.67% of the stock is owned by institutional investors and hedge funds.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.